Crizotinib-Resistant Mutants of EML4-ALK Identified Through an Accelerated Mutagenesis Screen

Activating gene rearrangements of anaplastic lymphoma kinase (ALK) have been identified as driver mutations in non-small-cell lung cancer, inflammatory myofibroblastic tumors, and other cancers. Crizotinib, a dual MET/ALK inhibitor, has demonstrated promising clinical activity in patients with non-s...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Sen, Wang, Frank, Keats, Jeffrey, Zhu, Xiaotian, Ning, Yaoyu, Wardwell, Scott D, Moran, Lauren, Mohemmad, Qurish K, Anjum, Rana, Wang, Yihan, Narasimhan, Narayana I, Dalgarno, David, Shakespeare, William C, Miret, Juan J, Clackson, Tim, Rivera, Victor M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2011
Materias:
Research Letters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3265718/
https://www.ncbi.nlm.nih.gov/pubmed/22034911
http://dx.doi.org/10.1111/j.1747-0285.2011.01239.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3265718/
https://www.ncbi.nlm.nih.gov/pubmed/22034911
http://dx.doi.org/10.1111/j.1747-0285.2011.01239.x

Ejemplares similares